<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00967941</url>
  </required_header>
  <id_info>
    <org_study_id>06-11-1879</org_study_id>
    <nct_id>NCT00967941</nct_id>
  </id_info>
  <brief_title>Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis</brief_title>
  <official_title>Vancomycin and Daptomycin Plus Cefazolin for Preoperative Vascular Surgery Prophylaxis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CAMC Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CAMC Health System</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study prospectively selects the patients to examine the effectiveness of the
      investigators' current standard of prophylaxis prior to vascular surgery and to compare the
      effectiveness of vancomycin and daptomycin plus cefazolin in reducing infections in vascular
      surgical patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to Medqic.org (site for the Surgical Care Improvement Project) the current
      recommended drug of choice for prophylaxis prior to vascular surgery is Cefazolin (Ancef).
      The exception would be to allow the use of Vancomycin as an acceptable antibiotic for
      patients undergoing cardiac, vascular or orthopedic surgery due to the increasing risk of
      methicillin-resistantStaphylococcus aureus (MRSA). The significance of the study is to
      demonstrate that MRSA coverage is needed in vascular surgery with prosthetic graft placement
      in areas of the body that is at high risk for infection. By decreasing post surgical site and
      prosthetic infections, we could significantly reduce vascular surgery mortality and
      morbidity. Cost and amputation rates we feel could also be reduced. patients will be
      randomized in three groups such as cefazolin,vancomycin and cefazolin, daptomycin and
      cefazolin and then patients will be monitored per usual post-operative course (30 days and 90
      days follow-up) with wound and incision evaluation. Outcome measures include hospital length
      of stay, the presence of a graft infection, skin infection at incision site, vascular
      procedure failure secondary to infection, cost, thirty day readmits, amputation, and
      mortality.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Number of Participants With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections.</measure>
    <time_frame>30 days post-operative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Groin Procedures in Patients With and Without Any Infection.</measure>
    <time_frame>30 days post-operative</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">169</enrollment>
  <condition>MRSA Infections</condition>
  <arm_group>
    <arm_group_label>Ancef</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin and Cefazolin</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Daptomycin and Cefazolin</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients 18 years of age and older undergoing a vascular surgery and or vascular access
        (vascular fistula or vascular graft) procedure were eligible for enrollment in the study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients greater than 18 years of age undergoing vascular surgery including carotid
             procedures and a vascular access procedure (Fistula or Graft).

        Exclusion Criteria:

          -  Patients with an allergy to daptomycin or vancomycin.

          -  Patients with chronic wounds.

          -  Prior colonization of MRSA.

          -  Increased MRSA rate facility wide.

          -  Continuous inpatient stay &gt;27 hrs prior to surgical procedure.

          -  Patients with active infection requiring antibiotics preoperatively.

          -  Patients with a history of MRSA colonization or infection, HIV, admission for &gt;3
             months in an acute care center or long-term care center, penicillin allergy or
             penicillin allergy and on dialysis.

          -  Dialysis patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick Stone, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CAMC Medical Staff-with admitting privileges</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vascular Center of Excellence</name>
      <address>
        <city>Charleston</city>
        <state>West Virginia</state>
        <zip>25304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 27, 2009</study_first_submitted>
  <study_first_submitted_qc>August 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2009</study_first_posted>
  <results_first_submitted>November 2, 2012</results_first_submitted>
  <results_first_submitted_qc>February 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 28, 2020</results_first_posted>
  <last_update_submitted>February 16, 2020</last_update_submitted>
  <last_update_submitted_qc>February 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>CAMC Health System</investigator_affiliation>
    <investigator_full_name>Patrick Stone, MD</investigator_full_name>
    <investigator_title>Patrick Stone, MD,</investigator_title>
  </responsible_party>
  <keyword>Vascular Surgery</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>recruitment was done during the period August 2007 through June 2009 at vascular center.</recruitment_details>
      <pre_assignment_details>12 patients were excluded from study for being ineligible due to active infection, dialysis, allergy to penicillin,NO procedure, withdrew from surgery.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ancef</title>
          <description>Ancef (Antibiotic Prophylaxis) : Comparing the antibiotic treatment related to surgery</description>
        </group>
        <group group_id="P2">
          <title>Daptomycin and Cefazolin</title>
          <description>Daptomycin and Cefazolin (Antibiotic Prophylaxis) : Comparing the antibiotic treatment related to surgery</description>
        </group>
        <group group_id="P3">
          <title>Vancomycin and Cefazolin</title>
          <description>Vancomycin and Cefazolin (Antibiotic Prophylaxis) : Comparing the antibiotic treatment related to surgery</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ancef</title>
          <description>Ancef (Antibiotic Prophylaxis) : Comparing the antibiotic treatment related to surgery</description>
        </group>
        <group group_id="B2">
          <title>Daptomycin and Cefazolin</title>
          <description>Daptomycin and Cefazolin (Antibiotic Prophylaxis) : Comparing the antibiotic treatment related to surgery</description>
        </group>
        <group group_id="B3">
          <title>Vancomycin and Cefazolin</title>
          <description>Vancomycin and Cefazolin (Antibiotic Prophylaxis) : Comparing the antibiotic treatment related to surgery</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="67"/>
            <count group_id="B2" value="54"/>
            <count group_id="B3" value="60"/>
            <count group_id="B4" value="181"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.37" spread="11.78"/>
                    <measurement group_id="B2" value="66.78" spread="11.81"/>
                    <measurement group_id="B3" value="64.36" spread="11.12"/>
                    <measurement group_id="B4" value="65.17" spread="11.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Number of Participants With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections.</title>
        <time_frame>30 days post-operative</time_frame>
        <population>Patients with MRSA infections.</population>
        <group_list>
          <group group_id="O1">
            <title>Ancef</title>
            <description>Ancef (Antibiotic Prophylaxis) : Comparing the antibiotic treatment related to surgery</description>
          </group>
          <group group_id="O2">
            <title>Daptomycin and Cefazolin</title>
            <description>Daptomycin and Cefazolin (Antibiotic Prophylaxis) : Comparing the antibiotic treatment related to surgery</description>
          </group>
          <group group_id="O3">
            <title>Vancomycin and Cefazolin</title>
            <description>Vancomycin and Cefazolin (Antibiotic Prophylaxis) : Comparing the antibiotic treatment related to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Number of Participants With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections.</title>
          <population>Patients with MRSA infections.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Groin Procedures in Patients With and Without Any Infection.</title>
        <time_frame>30 days post-operative</time_frame>
        <population>Patients with groin procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>Total Patients With Infection</title>
            <description>Total number of patients who have infections in the study.</description>
          </group>
          <group group_id="O2">
            <title>Patients Without Infection</title>
            <description>Total number of patients who do not have any infections.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Groin Procedures in Patients With and Without Any Infection.</title>
          <population>Patients with groin procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse Events were not collected and assessed as a part of this protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Patients</title>
          <description>The adverse event was counted for all patients instead of groups. Ideally no unexpected adverse events. All were known risks in vascular procedures.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We did not have standardization of skin preparation. Additionally, we did not have a specific protocol for dressing use and time of dressing removal. We excluded high-risk patients for MRSA infection in our study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Patrick Stone, MD</name_or_title>
      <organization>CAMC Health System</organization>
      <phone>304-388-8250 ext 9901</phone>
      <email>pstone0627@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

